Novartis' (NVS.US) "potential blockbuster" oral new drug application for a new indication in China
Market VisionThursday, Sep 5, 2024 9:30 am ET
1min read The National Medical Products Administration's (NMPA) Center for Drug Evaluation's (CDE) website has recently announced that Novartis (NVS.US) has received approval for its new indication application for ipicopan capsules. The specific indication has not been disclosed. Ipicopan is a specific oral complement factor B inhibitor. It was approved for its first indication in China in April this year, used to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH). This is the third application for the product in China, and public information speculates that the indication may be C3 glomerulopathy.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
_23f7f7eb1749627884277.png)
